Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
218 Leser
Artikel bewerten:
(1)

Persistence Market Research Pvt. Ltd.: Liquid Embolic Market is projected to experience a noteworthy 8.9% CAGR to reach a market valuation of approximately US$ 580.5 Mn by 2031

NEW YORK, Jan. 25, 2022 /PRNewswire/ -- The global liquid embolic market was valued at US$ 231.9 Mn in 2020, and is expected to exhibit a CAGR of around 8.9% over the forecast period (2021-2031).

Persistence_Market_Research_Logo

Embolization is a procedure that uses certain particles such as tiny gelatine sponges or beads to inhibit blood vessels. The embolization process is used to stop bleeding or inhibit the flow of blood to a tumour or an abnormal area of tissue. Tumor embolization, thus, is a process that is used for treating tumors by blocking blood supply to the tumor cells.

Availability of effective conventional, first-level therapies for the treatment of liver cancer, uterine fibroids, hemorrhagic stroke, and other hemorrhagic conditions is a key driver for market growth. Therapies such as surgery, chemotherapy, and radiation therapy are preferred options in cancer treatment.

Liquid embolic therapy has shown to be safe and effective with high success rate and less post-operative complications. Commercially available liquid embolics have been used to successfully treat hypervascular tumors, peripheral vascular lesions, and varicoceles.

Request for sample copy of report: https://www.persistencemarketresearch.com/samples/25513

According to Globocan, around 19.3 million cases of cancer were detected in 2020 globally. On the other hand, as per data published by Cancer.Net in 2021, liver cancer is the fifth-most-common cancer in men and the ninth-most-common in women. Rising prevalence of cancer and tumors such as brain tumor will drive demand for liquid embolics over the coming years.

Key Takeaways from Market Study

  • Liquid embolic vials, owing to their effectiveness in the storage of large volumes of liquid and ease of use, continue to hold the largest market. This product segment is expected to experience a CAGR of 9.6% through 2031.
  • Based on indication, brain arterio-venous malformations (bAVM) is leading with over 44% of market share.
  • Hospitals will dominate the liquid embolic market with a market share of nearly 60%.
  • By region, North America is slated to dominate the global market for liquid embolics with over 1/3 market share, while experiencing twofold growth over the decade.

Get customized report as per requirement: https://www.persistencemarketresearch.com/request-customization/25513

"Rising prevalence of tumours & cardiovascular diseases and new product launches & approvals are expected to drive market expansion over the coming years," says an analyst of Persistence Market Research.

Who is Winning?

Key market players such as Medtronic and Terumo, amongst others, are focusing on expansion in emerging regions by manufacturing and introducing new product lines in their already existing product portfolios.

  • OptiSphere embolization spheres launched in the U.S. by Medtronic (2018) is providing new treatment options for embolization of hypervascular tumours.
  • Launch of an intravascular aneurysm treatment device called WEB Embolization System in Japan by Terumo Corporation (2020).

Prominent liquid embolic product manufacturers include Medtronic, Meril Life Sciences Pvt. Ltd., Johnson & Johnson, Microvention Inc., Guerbet, and Emboflu.

Get full access of report: https://www.persistencemarketresearch.com/checkout/25513

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the liquid embolic market in its latest study, presenting a historical demand assessment of 2016 - 2020 and projections for 2021 - 2031.

The research study is based on the product (liquid embolic vials and liquid embolic prefilled injectables), indication (brain arterio-venous malformations, tumour embolization, radiology, and cardiology), and end user (hospitals, ambulatory surgical centers, and independent speciality centers), across seven key regions of the world.

Related Reports:

  • Chronic Thromboembolic Pulmonary Hypertension Market
  • Arteriovenous Fistula Market

About Persistence Market Research:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

Overview:

Persistence Market Research is always way ahead of its time. In other words, it tables market solutions by stepping into the companies'/clients' shoes much before they themselves have a sneak pick into the market. The pro-active approach followed by experts at Persistence Market Research helps companies/clients lay their hands on techno-commercial insights beforehand, so that the subsequent course of action could be simplified on their part.

Contact

Rajendra Singh
Persistence Market Research
U.S. Sales Office:
305 Broadway, 7th Floor
New York City, NY 10007
+1-646-568-7751
United States
USA - Canada Toll-Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Visit Our Website: https://www.persistencemarketresearch.com

Logo: https://mma.prnewswire.com/media/661339/Persistence_Market_Research_Logo.jpg

© 2022 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.